ArticleOncogenesis2025

Novel CDK2/CDK9 inhibitor fadraciclib targets cell survival and DNA damage pathways and synergizes with encorafenib in human colorectal cancer cells with BRAF(V600E).

Md Mohiuddin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.